These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26996115)

  • 1. Quantitative Evaluation of BAFF, HMGB1, TLR 4 AND TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis.
    Hamid KM; Nejati A; Shoja Z; Mollaei-Kandelousd Y; Doosti R; Mirshafiey A; Tafakhori A; Sahraian MA; Marashi SM
    Iran J Allergy Asthma Immunol; 2016 Feb; 15(1):75-81. PubMed ID: 26996115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN-α in patients with relapsing-remitting multiple sclerosis.
    Deckx N; Willekens B; Wens I; Eijnde BO; Goossens H; Van Damme P; Berneman ZN; Cools N
    Innate Immun; 2016 May; 22(4):266-73. PubMed ID: 27036414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
    Giacomini E; Severa M; Rizzo F; Mechelli R; Annibali V; Ristori G; Riccieri V; Salvetti M; Coccia EM
    Eur J Immunol; 2013 Jul; 43(7):1963-72. PubMed ID: 23636665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis.
    Malhotra S; Fissolo N; Tintoré M; Wing AC; Castilló J; Vidal-Jordana A; Montalban X; Comabella M
    J Neuroinflammation; 2015 Mar; 12():48. PubMed ID: 25879961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Training Improves the Expression Profile of Inflammation-associated Antimicrobial Peptides, MicroRNAs, and TLR-4 in Patients with Multiple Sclerosis.
    Yousefi Saqqezi S; Azamian Jazi A; Hemmati R; Jivad N
    Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):441-452. PubMed ID: 34418898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
    Kannel K; Alnek K; Vahter L; Gross-Paju K; Uibo R; Kisand KV
    PLoS One; 2015; 10(11):e0143393. PubMed ID: 26600308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential microRNA expression in blood in multiple sclerosis.
    Søndergaard HB; Hesse D; Krakauer M; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1849-57. PubMed ID: 23773985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation.
    Ittah M; Miceli-Richard C; Gottenberg JE; Sellam J; Lepajolec C; Mariette X
    Eur J Immunol; 2009 May; 39(5):1271-9. PubMed ID: 19337998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
    J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
    Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
    Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional characteristics of CD4+ T cells in multiple sclerosis: relative lack of suppressive populations in blood.
    Edström M; Mellergård J; Mjösberg J; Jenmalm M; Vrethem M; Press R; Dahle C; Ernerudh J
    Mult Scler; 2011 Jan; 17(1):57-66. PubMed ID: 20847001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.
    Liguori M; Fera F; Patitucci A; Manna I; Condino F; Valentino P; Telarico P; Cerasa A; Gioia MC; di Palma G; Quattrone A
    Brain Res; 2009 Feb; 1256():123-8. PubMed ID: 19071096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL2 induction by 1,25(OH)2D3 in dendritic cells from healthy donors and multiple sclerosis patients.
    Sanseverino I; Rinaldi AO; Purificato C; Cortese A; Millefiorini E; Gessani S; Gauzzi MC
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():102-5. PubMed ID: 24184699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary study of high mobility group box chromosomal protein 1(HMGB1) in ankylosing spondylitis patients.
    Chen Y; Sun W; Li S; Ni J; Su Y; Wang C; Luo X; Tu W; Shen G; Gong F; Zheng F; Dong L
    Clin Exp Rheumatol; 2015; 33(2):187-94. PubMed ID: 25602579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset.
    Glasnović A; Cvija H; Stojić M; Tudorić-Đeno I; Ivčević S; Romić D; Tičinović N; Vuletić V; Lazibat I; Grčević D
    Neuroimmunomodulation; 2014; 21(5):226-33. PubMed ID: 24603633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Giacomini E; Rizzo F; Etna MP; Cruciani M; Mechelli R; Buscarinu MC; Pica F; D'Agostini C; Salvetti M; Coccia EM; Severa M
    Mult Scler; 2018 Feb; 24(2):127-139. PubMed ID: 28273784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of suppressor of cytokine signaling 1 (SOCS1) gene dramatically increases in relapsing-remitting multiple sclerosis.
    Pahlevan Kakhki M; Rakhshi N; Heidary M; Behmanesh M; Nikravesh A
    J Neurol Sci; 2015 Mar; 350(1-2):40-5. PubMed ID: 25701091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy.
    Mohajeri M; Farazmand A; Mohyeddin Bonab M; Nikbin B; Minagar A
    Iran J Allergy Asthma Immunol; 2011 Sep; 10(3):155-61. PubMed ID: 21891821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.